Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the target of a large decrease in short interest in April. As of April 30th, there was short interest totalling 2,749,205 shares, a decrease of 2.6% from the April 15th total of 2,822,725 shares. Based on an average trading volume of 193,928 shares, the short-interest ratio is presently 14.2 days. Approximately 2.0% of the shares of the company are short sold.
Several research firms recently issued reports on PLX. Zacks Investment Research raised Protalix Biotherapeutics from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Tuesday, March 26th. HC Wainwright set a $3.00 price target on Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Tuesday, March 19th.
Shares of NYSEAMERICAN PLX opened at $0.41 on Wednesday. Protalix Biotherapeutics has a 1-year low of $0.27 and a 1-year high of $0.83.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last issued its earnings results on Monday, May 6th. The company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.02). The business had revenue of $10.44 million during the quarter, compared to analysts’ expectations of $10.15 million. During the same quarter in the previous year, the company earned ($0.06) earnings per share.
A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Virtu Financial LLC boosted its stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 44.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 91,862 shares of the company’s stock after buying an additional 28,236 shares during the period. Virtu Financial LLC owned 0.06% of Protalix Biotherapeutics worth $29,000 as of its most recent SEC filing.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Recommended Story: Different Options Trading Strategies
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.